R&D is the core of our innovation
In 2023, our R&D expenditure was £6.2 million, up 13.4% AER and 13.6% CER on 2022.
We’ve also strengthened our pipeline and technology capabilities through business development, seeking out new, differentiated opportunities in diseases with high patient need.
We have world-leading capabilities in vaccines and medicines development. Our pipeline is focused on delivering substantial and differentiated impact for patients – through new solutions not available today or potentially new standards of care. We are focused on combining scientific potential with unmet patient need and commercial value.
We are bringing stronger alignment to our core therapeutic areas and embedding tech to accelerate research to deliver our pipeline better and faster, positioning us to become the industry leader in technology-enabled research.
We prioritise flawless execution of our late-stage pipeline and acceleration of our organic pipeline to deliver innovation faster.
Technology powers our R&D. We use human genetics, functional genomics, along with artificial intelligence and machine learning to deeply understand the patient, human biology, and disease mechanisms.
We can access and analyse huge volumes of data beyond the ability of the human brain, to find connections and predict patterns in disease, and identify novel
How our R&D approach is getting us ahead of disease
Vaccines and medicines in the pipeline71
Number of assets in phase III/registration in 202318
Number of phase I programmes started in 20238
What therapeutic areas are we focusing on?
We prioritise research into vaccines and medicines across our four core therapeutic areas of infectious diseases, HIV, respiratory/immunology, and oncology. We also remain open to opportunities outside of these core areas where the science aligns with our strategic approach. We continue to strengthen our pipeline of vaccines and medicines, applying our growing expertise and partnerships in technology and data to increase the productivity of our R&D.
Our portfolio is the broadest in the industry and with HIV, accounts for two thirds of our pipeline
We work to end the global HIV epidemic with an industry-leading pipeline driven by patient insights
We push the frontiers of respiratory science to transform patient lives based on decades of research
We have an emerging portfolio and seek to make transformative breakthroughs in immuno-oncology